Volition Advances Nu.Q® NETs Platform Towards Commercialization
VolitionRx released a comprehensive update on its Nu.Q NETs platform, summarizing peer-reviewed clinical data that demonstrates the assay's ability to accurately distinguish sepsis from non-infectious inflammation and predict patient outcomes. The company highlighted a Total Addressable Market of approximately $3.8 billion on an annualized basis and confirmed it is in active discussions with several large diagnostic companies to accelerate development.
Key figures
- Tam annualized usd
- $3.8 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.